EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Circulating tumor DNA in early breast cancer: Evidence, challenges, next steps

Serena Di Cosimo iD, Valentina Appierto iD, Carolina Reduzzi, Loris De Cecco, Carmine Valenza, Lorenzo Gerratana, Elisa Agostinetto, Antonio Llombart-Cussac, Michail Ignatiadis, Javier Cortes, Massimo Cristofanilli, Nicola Fusco und 2 weitere

Cancer · 2026

DOI: 10.1002/cncr.70521 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer, 2026. Verfasst von Serena Di Cosimo und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Advanced Diagnostics, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. Hauptthemen laut MEDLINE: Breast Neoplasms, Circulating Tumor DNA, Biomarkers, Tumor. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 82 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Ministry of Health, Ricerca Corrente funds.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Circulating tumor DNA (ctDNA) is a tumor‐derived, circulating bioanalyte that can be detected in blood using minimally invasive, blood‐based biomarker procedures and has prognostic value in early breast cancer. Quantitative features of ctDNA, including baseline detectability and levels, have shown prognostic potential in early breast cancer by reflecting tumor burden and biologic aggressiveness, thereby supporting risk stratification. Post‐treatment ctDNA detection may identify minimal residual disease and can precede radiologic or symptomatic recurrence by several months to years. Nevertheless, ctDNA has not yet been adopted in routine clinical practice in early breast cancer, partly because of biologic constraints, including low and heterogeneous tumor DNA shedding, as well as pre‐analytical and analytical variability that can affect testing sensitivity. Ongoing efforts are focused on methodological standardization and clarification of the clinically actionable context. This narrative review examines the challenges in applying ctDNA to early breast cancer, spanning patient selection, sampling logistics, specimen handling, assay performance, and sources of assay failure. The authors outline determinants of ctDNA measurement that restrict the proportion of evaluable patients and limit translation to clinical practice and then summarize evidence supporting ctDNA for early response monitoring during neoadjuvant therapy, postoperative minimal residual disease detection, and longitudinal molecular surveillance. Finally, ctDNA‐guided therapeutic interception strategies and emerging multimodal cell‐free DNA approaches are discussed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsCirculating Tumor DNABiomarkers, TumorHumansFemaleNeoplasm, ResidualPrognosisEarly Detection of Cancer

Stichwörter der Autor:innen

circulating tumor DNAearly breast cancerminimal residual disease (MRD)precision oncologysurveillance

Substanzen

Circulating Tumor DNABiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Advanced Diagnostics, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Liquid Biopsy Platform, Division of Hematology/Oncology, Weill Cornell Medicine, New York, New York, USA.
  • Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Division of New Drug and Early Drug Development for Innovative Therapies, European Institute of Oncology IRCCS, Milan, Italy.
  • Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
  • Department of Medicine, University of Udine, Udine, Italy.

ORCID-Profile: Serena Di Cosimo, Valentina Appierto, Giuseppe Curigliano

Förderung

  • Ministry of Health, Ricerca Corrente funds

Zitieren

APA

Di Cosimo, S., Appierto, V., Reduzzi, C., De Cecco, L., Valenza, C., Gerratana, L., Agostinetto, E., Llombart-Cussac, A., Ignatiadis, M., Cortes, J., Cristofanilli, M., Fusco, N., Curigliano, G., & Pruneri, G. (2026). Circulating tumor DNA in early breast cancer: Evidence, challenges, next steps. Cancer. https://doi.org/10.1002/cncr.70521

Vancouver

Di Cosimo S, Appierto V, Reduzzi C, De Cecco L, Valenza C, Gerratana L, et al. Circulating tumor DNA in early breast cancer: Evidence, challenges, next steps. Cancer. 2026. doi:10.1002/cncr.70521

BibTeX
@article{DiCosimo2026,
  author = {Di Cosimo, Serena and Appierto, Valentina and Reduzzi, Carolina and De Cecco, Loris and Valenza, Carmine and Gerratana, Lorenzo and Agostinetto, Elisa and Llombart-Cussac, Antonio and Ignatiadis, Michail and Cortes, Javier and Cristofanilli, Massimo and Fusco, Nicola and Curigliano, Giuseppe and Pruneri, Giancarlo},
  title = {Circulating tumor DNA in early breast cancer: Evidence, challenges, next steps},
  journal = {Cancer},
  year = {2026},
  doi = {10.1002/cncr.70521}
}
Kostenlos starten →